Veracyte (VCYT) has drawn fresh attention after announcing Medicare coverage from CMS for its TrueMRD Monitoring Test for muscle-invasive bladder cancer, with commercial launch planned for June 1, 2026.

The Medicare decision and raised 2026 revenue guidance come after a mixed share price run, with Veracyte’s stock falling 4.8% over the past week but rising 13.9% over the past month and delivering a 31.8% total shareholder return over the last year.

If you are interested in how diagnostics and cancer testing tie into broader healthcare technology trends, this is a good moment to widen your search using our screener for 32 healthcare AI stocks.

With Veracyte’s stock up 31.8% over the past year and trading about 23% below consensus analyst targets, investors now face a key question: Is the latest Medicare win still underappreciated, or is future growth already priced in?

Most Popular Narrative: 18.1% Undervalued

Veracyte's most followed narrative pegs fair value at $47.00 compared with a last close of $38.48, putting the current Medicare news into a wider long term context.

Pipeline momentum, with five major product launches and a pivotal clinical study (OPTIMA) completing in the next 18 months, positions Veracyte to further diversify revenue, drive cross-selling, penetrate new markets (e.g., MRD in bladder cancer, Prosigna for breast cancer), and significantly expand addressable markets, supporting long-term topline acceleration.

Curious what sits behind that fair value gap? The narrative leans heavily on paired revenue and earnings growth, plus a richer future earnings multiple than the sector.

Result: Fair Value of $47.00 (UNDERVALUED)

However, that gap depends on Afirma and Decipher staying resilient, as well as on new tests like MRD and Prosigna securing payer coverage and meaningful physician uptake.

Another View: Earnings Multiple Sends a Different Signal

There is a clear tension between the 29.5% discount to an internal fair value estimate and where the market is currently pricing Veracyte on earnings. The stock trades on a P/E of 34.9x versus a fair ratio of 15.2x, the US Biotechs industry at 17.2x and a peer average of 28x.

That kind of premium can sometimes reflect confidence in the business, but it can also mean less room for error if growth or margins fall short of expectations. The key question for you is whether Veracyte’s story justifies paying so far above where the market could eventually settle.

Next Steps

With so many moving parts in this story, sentiment can shift quickly, so it helps to look at the numbers yourself rather than rely on headlines. To see what investors are currently optimistic about, review the 4 key rewards

Looking for more investment ideas?

Veracyte might be front of mind today, but you do not want to miss other potential opportunities that fit different goals, risk levels, and income needs.

• Target steady compounding with stocks that combine strong fundamentals and cleaner balance sheets using the solid balance sheet and fundamentals stocks screener (45 results).
• Spot potential mispricings by scanning companies that look attractively priced on key fundamentals through the 51 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies focused on higher-yield payouts in the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.